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The Vaginal Microenvironment: The
Physiologic Role of Lactobacilli
Emmanuel Amabebe and Dilly O. C. Anumba*
Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, United Kingdom
In addition to being a passage for sperm, menstruum, and the baby, the human vagina
and its microbiota can influence conception, pregnancy, the mode and timing of delivery,
and the risk of acquiring sexually transmitted infections. The physiological status of
the vaginal milieu is important for the wellbeing of the host as well as for successful
reproduction. High estrogen states, as seen during puberty and pregnancy, promote
the preservation of a homeostatic (eubiotic) vaginal microenvironment by stimulating the
maturation and proliferation of vaginal epithelial cells and the accumulation of glycogen.
A glycogen-rich vaginal milieu is a haven for the proliferation of Lactobacilli facilitated
by the production of lactic acid and decreased pH. Lactobacilli and their antimicrobial
and anti-inflammatory products along with components of the epithelial mucosal barrier
provide an effective first line defense against invading pathogens including bacterial
vaginosis, aerobic vaginitis-associated bacteria, viruses, fungi and protozoa. An optimal
host-microbial interaction is required for the maintenance of eubiosis and vaginal health.
This review explores the composition, function and adaptive mechanisms of the vaginal
microbiome in health and those disease states in which there is a breach in the
host-microbial relationship. The potential impact of vaginal dysbiosis on reproduction
is also outlined.
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INTRODUCTION
The vaginal mucosal ecosystem is comprised of a stratified squamous non-keratinized epithelium
overlaid by a mucosal layer continuously lubricated by cervicovaginal fluid (CVF). Together, these
form a daunting physical and biochemical barrier against extraneous invading organisms. Apart
from being an acidic medium containing an assortment of antimicrobial molecules including
antibodies (IgA and IgG), mucins, β-defensins, secretory leucocyte protease inhibitor (SLPI),
neutrophil gelatinase-associated lipocalin (NGAL), surfactant protein etc., CVF also facilitates the
confinement of exogenous organisms (summarized in Figure 1) (1–3).
The vagina also harbors numerous microorganisms (the “microbiota”), that exist (in
conjunction with their genes and products) in a regulated mutualistic relationship with the host
(the “microbiome”) (4). Some of these microorganisms such as Lactobacillus species reinforce the
defense against invasion and colonization by opportunistic pathogens. The composition of the
vaginal microbiota/microbiome is dynamic and undergoes changes corresponding with hormonal
fluctuations throughout the woman’s reproductive life, i.e., from puberty to menopause, and during
pregnancy (5).
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The normal physiological vaginal microbiota was initially
described in 1892 by Albert Döderlein as homogenous, consisting
of only Gram-positive bacilli (Doderlein’s bacilli) (6), believed
to originate from the gut and currently known to be a part of
the genus Lactobacillus (7). The evolution of this unique vaginal
microbiome is supported by two evolutionary hypotheses: the
“disease risk hypothesis” (8, 9), and the “obstetric protection
hypothesis” (9), which suggest that the human vagina is
selectively dominated by protective Lactobacillus species because
humans are more susceptible to sexually transmitted diseases;
and also at higher risk of pregnancy and parturition-associated
microbial complications (8–10).
A number of protective Lactobacillus species dominates the
healthy vaginal microbiota in most reproductive-age women.
Recent advances in DNA sequencing techniques have revealed
that the dominant Lactobacillus species in the vaginal microbiota
include L. crispatus, L. gasseri, L. iners, and L. jensenii, while
other anaerobes including Gardnerella, Atopobium, Mobiluncus,
Prevotella, Streptococcus, Ureaplasma, Megasphaera etc. able
to cause infections such as bacterial vaginosis (BV) are kept
dormant by the protective action of lactobacilli. These high-
resolution techniques have enabled the classification of the
vaginal microbiota into five community state types (CSTs) with
CSTI, II, III and V dominated by L. crispatus, L. gasseri, L. iners,
and L. jensenii respectively, while CSTIV is dominated by mixed
anaerobes similar to those found in BV (5, 11).
The prevalence of these organisms in the vaginal microbiota
vary in different race/ethnic groups and biogeographical
locations, with Blacks and Hispanics harboring more anaerobic
bacterial species (CSTIV) and showing higher vaginal pH in the
presence or absence of clinical infection (11, 12). Differences in
prevalence are also related to lifestyle differences (11) and gene-
environment interactions (12). Unlike other body viscera such as
the gut, increased diversity of the vaginal microbiota is linked
to increased susceptibility to disease and negative reproductive
outcomes (5, 13).
In addition to epithelial cells and microbiota, the vagina
also contains immune-related cells (such as neutrophils,
macrophages, T and B cells, natural killer (NK) cells, etc.) (14)
and specialized receptors, e.g., toll-like receptors (TLRs) and nod-
like receptors (NLRs), with which it recognizes the presence of
pathogenic microbial species (15). Microbial stimulation through
ligands such as lipopolysaccharide (LPS) that stimulates TLR-
4 triggers the release of cytokines and chemokines such IL-1β,
Abbreviations: CDC, cholesterol-dependent cytolysin; CRH, corticotropin-
releasing hormone; CSAIDs, cytokine suppressive anti-inflammatory drugs;
CVF, cervicovaginal fluid; EMMPRIN, extracellular matrix metalloproteinase
inducer; HIV, human immunodeficiency virus; HPA, hypothalamic-pituitary axis;
HPV, human papillomavirus; HSV, herpes simplex virus; IL, interleukin; LPS,
lipopolysaccharide; MAPK, mitogen-activated protein kinase; MIAC, microbial
invasion of the amniotic cavity; MIP, macrophage inflammatory protein; MMP,
matrix metalloproteinase; NF-κB, nuclear factor-κB; NGAL, neutrophil gelatinase-
associated lipocalin; NK, natural killer; NLR, nod-like receptor; NSAIDs, non-
steroidal anti-inflammatory drugs; PDE, phosphodiesterase; PGE2, prostaglandin
E2; PGF2α, prostaglandin F2α; PROM, premature rupture of membranes; PRRs,
pattern recognition receptors; PTB, preterm birth; PTL, preterm labor; RANTES,
regulated on activation normal T cell expressed and secreted; SLPI, secretory
leucocyte protease inhibitor; TLR, toll-like receptor; TNF, tumor necrosis factor.
IL-6, IL-8, and tumor necrosis factor-α (TNF-α). This release is
activated and regulated via a nuclear factor-κB (NF-κB)-mitogen-
activated protein kinase (MAPK) signaling pathway (15). Other
immune factors including macrophages, NK cells, helper and
cytotoxic T cells as wells as B-lymphocytes are subsequently
recruited to mount appropriate immune responses. Such
pathogen-stimulated inflammatory responses normally control
infection but can in some instances breach the mucosal surface
and facilitate transmission of some other infections such as HIV
(1). Therefore, vaginal communities dominated by anaerobes are
potentially associated with greater pro-inflammatory response
than L. crispatus, L. gasseri or L. jensenii (3, 5). However,
Lactobacilli and lactic acid via multiple mechanisms as discussed
below promote antimicrobial defense without inducing immune-
mediated inflammation unlike the pathogenic anaerobes (3).
THE EFFECT OF ESTROGEN ON THE
VAGINAL ECOSYSTEM
The prepubertal vaginal microbiome is dominated by anaerobes,
E. coli, diptheroids and coagulase-negative Staphylococci
and significantly lesser glycogen (5). At puberty, the rising
levels of estrogen promote the maturation, proliferation
and accumulation of glycogen in the vaginal epithelial cells.
Glycogen is catabolized by human α-amylase to maltose,
maltotriose and α-dextrines, which are then metabolized to
lactic acid by Lactobacillus species (Figure 1). This creates an
acidic environment (pH, 3.5–4.5) conducive for the growth of
Lactobacilli at the expense of other anaerobic bacterial species
(1, 5). Lactobacilli dominance decreases as estrogen levels decline
following menopause (16), and increases with vaginal estrogen
replacement therapy.
The vaginal microbiota in normal pregnancy is predominated
by Lactobacilli and is more stable than that in the non-
pregnant state (12, 17, 18). This can be explained by the
high level of estrogen during pregnancy resulting in increased
vaginal glycogen deposition which enhances the proliferation
of Lactobacilli-dominated vaginal microbiota (2). Also, studies
have shown that menstruation significantly reversibly alters the
vaginal microbial diversity, with about a 100-fold decrease in
L. crispatus and increase in L. iners, G. vaginalis, P. bivia, and
A. vaginae (19, 20). In essence, the normal acidic vaginal pH
in reproductive-age women is driven by estrogen, glycogen, and
Lactobacilli (1, 21–23).
An intriguing direct relationship between vaginal
ostrogenization and candidiasis in postmenopausal women
has also been reported (24). After menopause, estrogen-induced
vaginal epithelial glycogen accumulation is associated with
increased infection by Candida albicans that has glycogen as
a major substrate. Contrastingly, in premenopausal women
the activity of α-amylase that correlates with D- (but not L-)
lactic acid and production of SLPI, NGAL, hyaluronidase-1 and
matrix metalloproteinase (MMP)-8, was decreased in women
infected with C. albicans (25). Increased glycogen availability
secondary to exfoliation and lysis of glycogen-rich epithelial
cells into the vaginal lumen by extracellular matrix degrading
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FIGURE 1 | Eubiotic effect of estrogen and Lactobacillus species in the vaginal milieu. At puberty and during pregnancy, elevated levels of estrogen promote the
maturation of and deposition of glycogen in vaginal epithelial cells. Glycogen from exfoliated and lysed epithelial cells is catabolized by α-amylase in the vaginal lumen
to smaller polymers that are subsequently metabolized to lactic acid by Lactobacillus spp. Lactic acid and cytolysin produced by Lactobacilli stimulate the dissolution
of epithelial cells by lysis and enhance the availability of glycogen. Lactic acid acidifies the vaginal milieu favoring the proliferation of Lactobacilli and inhibiting the
growth of infection-associated organisms. This is reinforced by Lactobacilli through the production of hydrogen peroxide (H2O2), bacteriocins and biosurfactants, as
well as the inhibition of the physical attachment of pathogens to the epithelium by competitive exclusion and the promotion of the engulfment and degradation of
infected epithelial cells (autophagy). Additionally, there is concomitant production of mucins, immunoglobulins (secretory IgA and IgG), secretory leucocyte protease
inhibitor (SLPI), neutrophil gelatinase-associated lipocalin (NGAL), and β-defensins, and other antimicrobial proteins, which all together provide a formidable first line of
defense against infection. (CVF, cervicovaginal fluid; LDH, lactate dehydrogenase).
enzymes - hyaluronidase-1 and MMP-8, lactic acid and cytolysin
could enhance α-amylase activity (25). This effect of vaginal
ostrogenization, glycogen level and candidiasis in relation to
menopausal status is likely to be of physiologic importance and
necessitates further investigation.
LACTOBACILLI, SINE QUA NON OF
VAGINAL HOMEOSTASIS
Vaginal lactic acid is predominantly of bacterial origin (26).
Under the influence of estrogen, the vaginal epithelium produces
<15% of L-lactic acid (26), while lactobacilli are the major
source of both L- and D-lactic acid (27). Of the four most
common vaginal Lactobacillus species, only L. iners lacks the
ability to synthesize D-lactic acid and instead produces the L-
isomer (3). Vaginal levels of α-amylase (produced by endocervical
and fallopian tube cells) directly correlates with levels of D-
lactic acid and other vaginal epithelial antimicrobial peptides
such as SLPI and NGAL, but not with L-lactic acid (25). D-
lactic acid is more protective against vaginal dysbiosis than
L-lactic acid (27). Its levels are highest when L. crispatus is
the dominant specie and lowest when L. iners, Gardnerella
or Streptococcus predominate (27); and this partly accounts
for the higher protection against urogenital infections (28,
29) and adverse reproductive outcomes (30) conferred by
L. crispatus compared to L. iners. Lactic acid at physiological
concentrations (e.g., 110mM) acidifies vaginal secretions (to
pH levels < 4), enhances the protective activities of H2O2 and
bacteriocins (31, 32), and inhibits opportunistic infections such
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as G. vaginalis, Trichomonas vaginalis, Neisseria gonorrhoeae,
Chlamydia trachomatis, herpes simplex virus (HSV), human
papillomavirus (HPV), HIV etc. (33). Specifically, distinct from
its bactericidal activity D-lactic acid inhibits Chlamydia infection
through a pH-dependent effect on the vaginal epithelial cells
and microenvironment (34). This conclusion arose from the
significantly greater protection against chlamydia provided by
L. crispatus, L. gasseri, and L. jensenii (34) that produce more D-
lactic acid than L. iners that produces predominantly L-lactic acid
(35). Also, D-lactic acid prevents upper genital tract infection by
modulating the L-lactic acid-induced production of extracellular
matrix metalloproteinase inducer (EMMPRIN) from vaginal
epithelial cells, and inhibiting the production of MMP-8 (27).
The precise mechanism of the bactericidal activity of
Lactobacillus is unclear but there is evidence that it is mediated
through the protonated forms of both D- and L-lactic acid
and not the lactate anion (36). At a pH value < pKa 3.9,
the protonated or uncharged form of lactic acid predominates.
Because it is a weak acid, 50% of lactic acid dissociates into lactate
anion and H+ at a pH of 3.86. Lactic acid in its protonated
form is membrane-permeant and unlike the lactate anion, does
not require the proton-linked monocarboxylate transporters or
the lactate-binding GPR81 receptors to enter cells (37, 38).
Lactic acid preferentially lyses bacteria other than Lactobacillus
species (23, 36); and causes bacterial cell death by acidifying
the cytosol, disrupting intracellular function (39), increasing the
permeability of the cell membrane to H2O2, diacetyl etc., thereby
potentiating the antimicrobial effect of other substances (40).
The reduced antimicrobial activity of lactic acid and increased
risk of infection associated with unprotected sexual intercourse
and menstruation could be attributed to the increase in vaginal
pH after deposition of seminal fluid and flow of menstruum,
which leads to formation of more lactate anion that has less
antimicrobial and immunomodulatory activities (33, 36).
Lactic acid also performs some immunomodulatory actions
on the genital tract mucosa and other cell types (41, 42). Lactic
acid in its protonated form creates an anti-inflammatory state
by stimulating the production of large amounts of the anti-
inflammatory cytokine IL-1RA, and inhibiting the production
of inflammatory cytokines (IL-6 and TNFα) and chemokines
(IL-8, RANTES and macrophage inflammatory protein-3α, MIP-
3α) in the presence of TLR-2,−3,−4 agonists (41). Lactic
acid also inhibits nuclear translocation and activation of the
transcription factor NF-κB in peripheral blood mononuclear
cells and monocytes/macrophages (43, 44). It is worth noting
that both D- and L-lactic acid exercise these anti-inflammatory
effects that are enhanced by low pH < 3.86 by directly acting on
cervicovaginal epithelial cells (41, 42).
Also, both D- and L-lactic acid can enhance vaginal epithelial
cell survival by facilitating the repair of damaged DNA through
the inhibition of histone deacetylase activity leading to increased
acetylation of histones on the surface of DNA (45, 46). This
epigenetic regulation of gene expression (45) permits the
transcription of genes that were previously blocked and possibly
promotes the secretion of components of the antimicrobial
innate immune system, such as NGAL from vaginal epithelial
cells, that selectively prevent the growth of bacteria other than
lactobacilli (3, 47). These observations show great promise for
the use of lactic acid-containing microbicides for therapeutic
restoration of vaginal homeostasis and prevention of STIs
including HIV.
Lactobacilli (apart from L. iners) produce hydrogen peroxide
(H2O2), which inhibits the growth of catalase-negative anaerobic
organisms by production of hydroxyl free radicals (48, 49).
They can also bind to the surface of vaginal epithelium and
competitively prevent other microbes from attaching to and
infecting the cells. Lactobacilli can produce other antimicrobial
peptides such as bacteriocins, bacteriocin-like substances
and biosurfactants; and promote autophagy (engulfment and
degradation) of intracellular bacteria, viruses and protozoa
(Figure 1) (27). Hence, through these mechanisms, lactobacilli
inhibit the growth of other potentially pathogenic endogenous
vaginal bacteria and prevent the acquisition of exogenous
bacteria. For these reasons a lactobacilli-dominated vaginal
microbiota has been described as healthy and necessary for the
overall wellbeing of the woman. However, it is important to note
that about 25% of women ostensibly maintain healthy vaginal
microbiota without lactobacilli dominance. These women
have been found to harbor other lactic acid producers such
as Atopobium, Megasphaera, Leptotrichia, Streptococcus, and
Staphylococcus (50, 51).
In addition, the degree of protection conferred on the vaginal
ecosystem is dependent on the predominant Lactobacillus specie.
For example, an L. iners-dominated vaginal microbiota is usually
associated with dysbiosis and appears less stable and more prone
to transition. In contrast L. crispatus that produces both D-
and L-lactic acid is associated with increased vaginal community
stability (less likely to transit to dysbiosis) and health (19, 52,
53). L. iners exhibits pathogenic propensity via its pore-forming
cholesterol-dependent cytolysin (CDC, inerolysin) (54, 55). It has
a small genome and is unable to produce D-lactic acid and H2O2
required to promote eubiosis, unlike the other Lactobacillus
species (3, 13). Also, we recently observed that preponderance
of L. jensenii (which produces only the D-Lactic acid and
lesser protective capacity compared to L. crispatus) (27), was
associated with decrease in lactate, succinate and increased risk
of premature delivery (56).
THE INFLUENCE OF MICROBIAL ACTIVITY
ON THE VAGINAL MUCOSAL BARRIER
FUNCTION
The mucosal surface of the vagina is an immunological and
physical barrier that prevents potential pathogens from coming
in contact with vaginal epithelial cells. It contains glycosylated
mucus proteins (sialoglycoproteins) such as mucin that provide
a dense lubricated physical barrier, which inhibits epithelial
cell-pathogen contact; and secretory immunoglobulin A (sIgA)
and IgG that recognize and neutralize antigenic microbial
products. Anaerobes associated with vaginal infection such as
G. vaginalis secrete sialidase that degrades mucus by cleaving
sialic acid from the glycoproteins. Sialic acid is taken up and
neutralized by G. vaginalis (foraging) to further circumvent the
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host response. A significant depletion of mucus sialic acids is seen
in BV-infected women compared to their healthy counterparts
with Lactobacillus-dominated microbiota (57). Degradation and
depletion of the components of the mucosal protective barrier
permits ascending upper genital tract infection. In addition, like
L. iners, G. vaginalis also produce a CDC called vaginolysin with
which it forms pores in the vaginal epithelium, which further
obliterates the protective barrier. Contrarily, the protective
function of the mucus layer is enhanced by L. crispatus-
dominated microbiota thereby hindering the penetration of
pathogens like HIV, whereas L. iners-dominated microbiota
facilitates the penetration of HIV. Therefore, alterations in the
composition of the vaginal microbial community significantly
affects the integrity of the protective mucosal surface layer (5).
STRESS AND VAGINAL HEALTH
The influence of stress on vaginal immunity has been the subject
of much speculation. Immune response may be impaired by
stress-related activation of the hypothalamic-pituitary adrenal
(HPA) axis and secretion of corticotropin-releasing hormone
(CRH) from the hypothalamus, which activates the release
of cortisol from the adrenal cortex and noradrenaline from
sympathetic nerve terminals (58). Cortisol inhibits the estrogen-
associated vaginal epithelial maturation and accumulation of
glycogen and consequently reduces lactobacilli dominance, while
noradrenaline acts synergistically with immune mediators to
potentiate the release of cytokines. The stress-induced increase
in cortical hormones - cortisol and deoxycorticosterone - and
the resultant decrease in lactobacilli abundance can worsen
vulvovaginal symptoms of infection (59). Reduced vaginal
epithelial glycogen decreases the production of lactic acid
and loss of its anti-inflammatory activities. Hence, a dysbiotic
vaginal flora is created characterized by a reduction or loss of
lactobacillus dominance. Concomitant increase in noradrenaline
potentiates the pro-inflammatory response and proliferation of
pathogenic strict and facultative anaerobes as well as other STIs.
Ultimately, stress exacerbates the susceptibility and severity of
vaginal infection (3).
ABERRANT VAGINAL MICROBIOTA
(DYSBIOSIS)
The vaginal microbiota is a dynamic community of diverse
bacterial species repeatedly subjected to both internal and
external manipulative stimuli such as changes in sex hormone
levels and stage of the menstrual cycle, sexual activity, antibiotic
therapy and the use of oral contraceptives, vaginal douching,
menopause, pregnancy, lactation, diabetes mellitus and stress.
The composition of the vaginal microbiota is also determined by
gene-environment interactions. Vaginal bacterial communities
devoid of Lactobacillus dominance with higher pH and lower
H2O2 have been observed to be normal in Black and Hispanic
women (11, 52, 60, 61).
The most common vaginal infection in reproductive-aged
women is bacterial vaginosis (BV). BV, with a prevalence rate
of 5–70% (62), is characterized by a depletion of lactobacilli
in favor of potentially pathogenic mixed anaerobes such as
Gardnerella, Atopobium, Mobiluncus, Prevotella, Streptococcus,
Mycoplasma, Ureaplasma, Dialister, Bacteroides etc. (63–65). It
creates a more heterogeneous vaginal environment associated
with decreased lactic acid levels, pH > 4.5, and high amounts
of short chain fatty acids (SCFAs) such as acetate, butyrate,
propionate and succinate produced by anaerobes. Although an
overt inflammatory response is often not manifest, it has been
associated with increased levels of immune mediators such as IL-
1β, IL-2, IL-6, IL-8, IL-10, TNF-α, Interferon (IFN)-γ, RANTES
etc. (1, 5), and decreased concentration of antimicrobial peptides
like NGAL (47). BV is an enigmatic syndrome with unidentified
etiology. Most BV-positive women are usually asymptomatic.
However, symptoms could appear in the form of a non-itchy
but irritating, creamy vaginal discharge with a fishy odor that
may be more prominent after sexual intercourse and during
menstruation.
The Amsel criteria are used to diagnose BV in most clinical
settings. The criteria include the evaluation of vaginal acidity,
the presence of vaginal discharge, the appearance of clue cells
(desquamated vaginal epithelial cells studded with anaerobic
bacteria), and a positive “whiff test” (a characteristic “fishy”
odor perceived when 10% potassium hydroxide is added to a
microscopic slide of vaginal discharge) (66). The most sensitive
criteria are the vaginal pH (>4.5) and the detection of thin,
homogenous, milky and adherent discharge (97%), when the
criteria are assessed individually (67). However, the detection
of discharge had a low specificity (26%) and positive predictive
value (27%), while the criterion with the highest specificity
was the presence of clue cells (86%). When combined together,
the presence of at least three criteria significantly increases the
likelihood of making an accurate diagnosis of BV, yielding a
sensitivity and specificity of 97 and 90% respectively (67, 68).
In the research space, BV is commonly diagnosed with the
Nugent scoring system (69). Although the diagnosis requires
experienced laboratory staff to evaluate the slides, it is more
objective and reliable and has a higher reproducibility and
sensitivity compared to the Amsel criteria (70). It employs
the Gram stain to microscopically identify a shift in vaginal
microbiota from healthy lactobacilli dominance (Gram-positive
rods) to an intermediate level of mixed Gram negative/variable
microbiota (Gardnerella and Bacteroides), to absence of
lactobacilli and predominance of Gram negative/variable rods or
curved rods (Mobiluncus) (68, 69). A score of 0–3 is consistent
with lactobacillus dominance and vaginal health, a score of 4–6
indicates an intermediate, mixed vaginal bacterial community,
whereas >7 indicates BV infection. There is a good correlation
between clinical features of BV and Gram stain scores (70).
BV is associated with increased risk of acquisition of STI such
as N. gonorrhoea, C. trachomatis, T. vaginalis, HSV, HPV, and
HIV, and other infections such as pelvic inflammatory disease,
endometritis, chorioamnionitis, and amniotic fluid infection.
In relation to pregnancy, BV appears to be associated with
preterm premature rupture of membranes (PPROM), preterm
labor (PTL) and preterm birth (PTB, i.e., delivery before 37
completed weeks of gestation) (62, 71–81).
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Vaginal dysbiosis can also manifest as aerobic vaginitis (AV).
It is an equally disruptive infection of the normal vaginal
Lactobacillus-dominated microbiota but is characterized by overt
inflammation, leukocyte and parabasal cell infiltration and
proliferation of enteric aerobic bacterial organisms including
Escherichia coli, Enteroccoci, Staphylococcus aureus, and group
B Streptococcus (21, 82). It has been described as the aerobic
equivalent of BV, due to decreased lactic acid concentration
secondary to depleted Lactobacillus dominance. However,
because anaerobes are absent, succinate concentration is low.
AV has also been associated with STIs such as C. trachomatis,
N. gonorrhoeae, and T. vaginalis. The clinical features of AV
include: red vaginal mucosal inflammation, increased IL-1β and
IL-6, vaginal pH> 6, itching and burning (pruritus), dyspareunia
and yellowish sticky discharge devoid of fishy odor. AV is
present in 2–25% of women and has been associated with
severe adverse gynecological and obstetric outcomes including
ascending genital infection/inflammation, PPROM, PTL and
PTB (83, 84).
IMPLICATIONS OF ABNORMAL VAGINAL
MICROBIOTA FOR HUMAN PREGNANCY
The physiological status of the vaginal milieu is crucial not just
to the general wellbeing of the host but also for conception
and eventual success of pregnancy. The ability of Lactobacillus
to preclude the invasion and colonization of the vaginal
space by pathogens without triggering an overt inflammatory
response is termed Tolerance and is particularly beneficial for
reproduction (3). Apart from increasing the host’s susceptibility
to STIs and other gynecological conditions including cervical
intraepithelial neoplasia and cervical cancer (85–87), a dysbiotic
vaginal microenvironment with degraded Lactobacilli-mediated
tolerance and anti-inflammatory mechanisms also influence the
course and outcome of pregnancy. In essence, Lactobacillus spp.
is invaluable to the preservation of a homeostatic vaginal milieu.
Conception and Miscarriage
Diminished vaginal Lactobacillus dominance has been linked
to failure of in vitro fertilization (IVF) and miscarriage (88).
Decreased conception rates and high rates of early pregnancy loss
due to reduced concentration of H2O2-producing Lactobacilli
and BV infection have been observed. The percentage of women
who deliver a live birth after undergoing embryo transfer
is greatly influenced by the microbial composition of the
cervicovaginal space. Increased pregnancy loss at 10–16 weeks in
spontaneous pregnancies (88) and early pregnancy loss (before
6 weeks) after IVF (89, 90) are associated with the presence of
a dysbiotic vaginal microbiota during gestation. There is a high
(30–40%) prevalence of abnormal vaginal microbiota in women
undergoing IVF (89, 91, 92). Low pregnancy rate (18%) and
increased pregnancy loss (up to 66%) was recorded in women
undergoing IVF when S. viridans was present in the transfer
catheter tip (92), while high live birth rates (up to 70%) and
low or no pregnancy loss were observed with the presence of
H2O2-producing Lactobacillus in the vagina and transfer catheter
tip. An even lower clinical pregnancy rate (9%) associated with
abnormal vaginal microbiota was observed in a recent study (93).
The role of infection-induced inflammation of the endometrial
lining and gestational tissues (chorioamniotic membranes and
placenta) was implicated (88). However, this plausible association
requires further investigation to unravel its pathogenesis in order
to improve conception and live birth rates.
Prematurity
Pregnancy is characterized by increased vaginal Lactobacillus
dominance due to heightened estrogen-stimulated glycogen
deposition and subsequent breakdown to lactic acid (Figure 1)
(6, 12, 17). Also, tolerance mechanisms including lactic acid-
induced autophagy of bacteria, viruses and protozoa, and
lactobacilli inhibition of pro-inflammatory mediators are up-
regulated during gestation (94, 95). Therefore, in the event
of disturbance of this homeostatic vaginal host-microbial
interaction during gestation (e.g., due to BV or AV), these
protective mechanisms are diminished and invasion and
colonization of the genital tract by pathogenic organisms can
occur. These organisms can stimulate the degradation of the
host mucosal epithelial barrier and cervical plug via the release
of proteolytic enzymes such as elastase, mucinase, sialidase,
protease, prolidase, and collagenases; ascend through the cervical
canal and gain access into the uterine cavity and compromise
the integrity of the fetal membranes (96–100). Ascending
intrauterine infection earlier in gestation accounts for about
50% of spontaneous PTBs (2, 77), as does chorioamniotic-
decidual inflammation (101). This occurs via the release of pro-
inflammatory cytokines and chemokines (e.g., TNF-α and β, IL-
1α and β, IL-2, IL-6, IL-8, RANTES etc.), prostaglandins (PGE2
and PGF2α), matrix metalloproteinases (MMPs- 1, 2, 3, 8, and
9), CRH, which trigger uterine contraction, membrane activation
(i.e., separation of fetal membranes from the decidua) and
cervical remodeling and effacement. An undesirable positive feed
forward mechanism is established which culminates in PPROM,
PTL and PTB (Figure 2) (49, 102). Central to these labor-
associated processes (at both term and preterm) is the pleotropic
transcription factor—NF-κB. It is activated by the recognition
of microbial products (e.g., LPS) and non-microbial products
by TLR/NLR, and regulates the expression of pro-inflammatory
cytokines, prostaglandins and MMPs (15, 103).
Interestingly, D-lactic acid produced exclusively by
Lactobacillus spp.—L. crispatus, L. jensenii, and L. gasseri—
in the vagina, inhibits the synthesis of MMP-8 by modulating
the action of EMMPRIN produced by vaginal epithelial cells
(27). This prevents cervical tissue digestion and decreases the
possibility of an ascending intrauterine infection and microbial
invasion of the amniotic cavity (MIAC). Also, the protective
function of the vaginal epithelial mucus layer is enhanced
(5) and heightened autophagy activity (3) is observed when
the vaginal microbiota is predominated by L. crispatus. An
L. crispatus-dominated vaginal microbiome as seen in most
healthy pregnancies is also inhibitory to E. coli colonization
of the genital tract (104), and can prevent AV (83, 84). This is
indicated to be via proteins produced by L. crispatus – S-layer,
bacterial surface layer and cell separation proteins; and L. jensenii
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FIGURE 2 | Pathogenesis of infection/inflammation-associated preterm labor and birth. Colonization of the female genital tract by pathogenic anaerobic bacteria due
to an altered vaginal microbiota triggers a feed forward inflammatory response that ultimately stimulates the pathways to preterm labor and delivery, i.e., uterine
contraction, cervical remodeling and membrane activation. CRH, corticotropin-releasing hormone; IL, interleukin; MIAC, microbial invasion of amniotic cavity; PGE2,
prostaglandin E2; PGF2α, prostaglandin F2α; TNF, tumor necrosis factor.
– adhesion exoprotein (105). In contrast, a low E. coli inhibitory
activity was observed in women with L. iners dominance
irrespective of pregnancy status (104), as this does not produce
D-lactic acid. However, this observation still requires further
investigation because in African women in whom the relative
abundance of L. crispatus is low (11, 104), E. coli inhibitory
activity is indicative of inflammation and increased susceptibility
to HIV (106, 107). It is also worth noting that even in healthy
women, there are ethnicity-dependent significant variations in
the vaginal microbiome (108). Additionally, L. crispatus and
L. jensenii inhibit the expression of pro-inflammatory mediators
in the presence of TLR agonists (1). However, the mechanism
through which this is achieved is unclear and the implications
for reproductive outcomes may differ between these two species.
Indeed, we recently observed an association between L. jensenii
dominance, decreased lactate and succinate, and spontaneous
PTB, while L. crispatus and L. gasseri were associated with
elevated lactate and succinate, and delivery at term (56). We have
also demonstrated a decrease in IL-8 and acetate levels (a marker
of vaginal dysbiosis and imminent PTB) (1, 109–111) when
L. crispatus is co-cultured with either G. vaginalis or M. curtisii
(112).
A plausible explanation for these species-dependent varied
outcomes could be the differential expression of lactic acid
isomers by L. crispatus, L. jensenii, and L. iners in synergy with
vaginal epithelial cells as described in earlier sections of this
article. In addition to acidifying the vaginal milieu and inhibiting
the growth of pathogenic anaerobes, both L- and D-lactic acid
isomers (protonated form) exhibit anti-inflammatory properties
by stimulating increased levels of IL-1RA without a concomitant
increase in IL-1β, IL-6, IL-8, TNFα, RANTES, and MIP-3 α
(41). They also attenuate the production of pro-inflammatory
mediators stimulated by TLR agonist (41, 113, 114). Though
both isomers exhibit similar virucidal and bactericidal activity
against HIV-1 and BV-associated bacteria respectively (41, 42),
D-lactic acid shows superior microbicidal capacity than the L-
isomer (27, 115), and has been advocated as a prebiotic in
the treatment of BV and prevention of PTB (2). The superior
protective capacity of L. crispatus is attributable to its ability to
produce both isomers of lactic acid. Taken together, the protective
functions of L. crispatus and/or its products could be annexed
through more comprehensive studies at different climates to
develop therapeutic strategies for maintaining vaginal health and
improving reproductive outcomes.
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CONCLUSION
A healthy vaginal milieu requires an optimum balance of the
host-microbial interaction despite multiple and sometimes
inevitable internal and external stimulations it receives.
Alteration of this homeostatic state, perhaps due to failure
of the host adaptive responses results in dysbiosis with
reproductive consequences if left unattended. These manifest as
decreased conception rates especially with assisted reproductive
technology, early pregnancy loss, and premature labor and
delivery. Though dysbiotic conditions such as BV also increase
the rate of PTB up to 7-fold, especially when diagnosed before 16
weeks of gestation (70), most BV-infected pregnant women do
not deliver prematurely (116). Also, a considerable proportion
of women with inflammation of the gestational tissues who
deliver preterm do not have BV (100). There is a growing body of
evidence suggesting that it is the relative quantities (abundance)
of bacteria, rather than just their presence (64, 117), and the
unique host immune response to the infectious stimuli, that are
associated with increased risk of infection and PTB (64, 118).
Host differences in distribution of Lactobacillus spp. innate
and adaptive immunity, volume and composition of vaginal
fluid, expression of epithelia cells surface ligands, as well as
other human behaviors and practices (such as smoking, sexual
intercourse, douching, contraceptive and antibiotics use etc.)
have been implicated in the variations in the composition of
the “normal” vaginal microbiota. Risk of infection and PTB is
modified by variations in maternal/fetal genetic composition
and epigenetics, which ultimately determines the intensity of
immune response to altered vaginal microbiota during gestation
(119–125). These discrepancies have created a huge burden on
the development of effective preventive and therapeutic strategies
to improved women’s health. As inflammation may continue
optimally even after the stimuli (e.g., bacterial infection) has
been treated, dual administration (cotreatment) of antibiotics
and anti-inflammatory agents such as TNF biologics, CSAIDs
– cytokine suppressive anti-inflammatory drugs (NF-κB and
MAPK inhibitors) (126–128), PDE inhibitors, glucocorticoids,
NSAIDs (15, 129, 130) should be explored.
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